Alnylam Pharmaceuticals (ALNY) Panoramica del titolo
Alnylam Pharmaceuticals, Inc. scopre, sviluppa, produce e commercializza farmaci terapeutici basati sull'interferenza dell'acido ribonucleico negli Stati Uniti, in Europa e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 5/6 |
| Prestazioni passate | 3/6 |
| Salute finanziaria | 5/6 |
| Dividendi | 0/6 |
ALNY Community Fair Values
Create NarrativeSee what 58 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Alnylam Pharmaceuticals, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$296.11 |
| Massimo di 52 settimane | US$495.55 |
| Minimo di 52 settimane | US$245.96 |
| Beta | 0.38 |
| Variazione di 1 mese | -7.13% |
| Variazione a 3 mesi | -12.68% |
| Variazione di 1 anno | 14.16% |
| Variazione a 3 anni | 39.64% |
| Variazione a 5 anni | 125.52% |
| Variazione dall'IPO | 4,826.96% |
Notizie e aggiornamenti recenti
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
May 01
ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.
ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.Recent updates
Alnylam Pharmaceuticals: The RNAi Leader Continues To Grind Through A Quieter Year
May 01ALNY: Fair View Balances TTR Execution Uncertainty With Cardiovascular Pipeline Progress
Analysts have trimmed the Alnylam Pharmaceuticals fair value estimate to $310 from $322.59, reflecting a series of reduced price targets and higher discount-rate assumptions, even as revenue growth expectations remain higher and long term profit margins and future P/E forecasts are more moderate. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed setup where confidence in the RNAi platform and the Amvuttra franchise is balanced against tighter valuation views and more conservative long term assumptions.ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' analyst price targets have been reset across the Street, with several cuts from firms now clustering in a roughly $249 to $570 range, as analysts balance concerns that shares are "priced to perfection" and that long term expectations may be too rich, against continued confidence in the RNAi platform and the strong Amvuttra launch in TTR and ATTR-CM. Analyst Commentary Recent research updates show a split tape on Alnylam, with some firms trimming targets and others leaning into the story as Amvuttra execution and RNAi platform confidence remain central themes.ALNY: TTR Franchise Momentum Will Support Confidence In 2026 Revenue Outlook
Alnylam Pharmaceuticals' updated analyst price targets show a wide reset across the Street, with cuts from firms now clustered around the $249 to $570 range. Analysts are balancing strong Amvuttra momentum and the RNAi platform's potential with concerns that the shares had been priced for very optimistic growth and competition assumptions.ALNY: TTR Execution Will Support Confidence In 2026 Revenue Outlook
Analysts have trimmed their fair value estimate for Alnylam Pharmaceuticals by $14 to $566, reflecting higher discount rates and more conservative assumptions for revenue growth and profit margins, even as they continue to highlight strong Amvuttra traction and supportive 2026 guidance in recent research. Analyst Commentary Recent research paints a mixed picture on valuation, but there is still a clear cluster of optimistic views around Alnylam's execution, especially in its TTR franchise and Amvuttra rollout.ALNY: Fair View Weighs TTR Franchise Guidance Against Launch Execution Risks
The updated analyst price target for Alnylam Pharmaceuticals has decreased by about $45 per share, as analysts refresh their models with slightly softer revenue growth assumptions, a modestly higher long-term profit margin, and a reduced future P/E multiple. Analyst Commentary Recent Street research on Alnylam Pharmaceuticals points to a mixed backdrop, with several firms revisiting their models following Q4 results, preannounced revenue figures, and updated 2026 guidance.ALNY: TTR Franchise Execution Will Support Confidence In 2026 Revenue Guidance
Analysts have trimmed their average price targets on Alnylam Pharmaceuticals by roughly $35 to $70, largely reflecting updated views on Amvuttra revenue trajectories, competitive pressures in ATTR-CM and recent guidance that, while still supported by continued TTR franchise momentum, has prompted more measured growth assumptions. Analyst Commentary Recent research updates show a mixed but generally constructive tone on Alnylam, with several bullish analysts pointing to execution on the TTR franchise, early Amvuttra traction in ATTR-CM and management guidance as key supports for valuation.ALNY: TTR Franchise Momentum Will Drive 2026 Revenue Guidance Confidence
Narrative Update: Alnylam Pharmaceuticals Price Target Revision The analyst price target for Alnylam Pharmaceuticals has been raised by $10 to $580, as analysts weigh mixed target changes across the Street alongside company guidance that highlights ongoing momentum in the TTR franchise and a positive outlook for revenue driven by Amvuttra. Analyst Commentary Recent Street research around Alnylam Pharmaceuticals has been active, with several price target revisions and fresh commentary following the company’s Q3 results, preliminary Q4 figures, and updated 2025 and 2026 revenue guidance.ALNY: Fair View Balances TTR Guidance Upside And Launch Deceleration Risk
Alnylam Pharmaceuticals' analyst fair value estimate has been raised from about $259.89 to about $368.22, as analysts factor in stronger modeled revenue growth, higher projected profitability, and a reset to more moderate future P/E expectations following recent research updates around Amvuttra uptake and revised TTR guidance. Analyst Commentary Recent research on Alnylam highlights a mixed backdrop.
ALNY: Cardiomyopathy Launch Will Drive Future Upside Despite Growing Competitive Pressures
Analysts have modestly lifted their price target for Alnylam Pharmaceuticals, reflecting stronger Amvuttra driven TTR revenue expectations and a series of Street target increases into the mid 400s to mid 500s, even as they highlight a more balanced risk and the potential for range bound trading into 2026. Analyst Commentary Recent Street research reflects a constructive but increasingly balanced view on Alnylam, with multiple firms lifting price targets into the mid 400s to mid 500s on the back of stronger Amvuttra traction and higher TTR revenue expectations, while also flagging valuation and competitive considerations that could cap upside.ALNY: Cardiomyopathy Launch Will Drive Future Momentum Despite Intensifying Competition
Alnylam Pharmaceuticals’ fair value estimate has nudged higher to approximately $493 from about $489 as analysts lift price targets into the mid to high $400s, citing stronger than expected Amvuttra driven TTR revenue growth and a still rich but increasingly supported long term earnings profile. Analyst Commentary Street research remains broadly constructive on Alnylam, with multiple firms lifting price targets into the mid to high $400s and several pushing above $500.ALNY: Future Momentum In Cardiomyopathy Will Meet Rising Competition And Pricing Pressures
The analyst price target for Alnylam Pharmaceuticals has increased by approximately $9 to $489, as analysts cite strong Amvuttra sales, raised revenue guidance, and resilient commercial momentum as key factors supporting a more optimistic outlook. Analyst Commentary Analysts have provided a range of perspectives following Alnylam Pharmaceuticals’ recent performance, with several raising their price targets and highlighting both catalysts and areas of caution for the company’s outlook.ALNY: Momentum In Cardiomyopathy Segment Will Face Intensifying Competitive Risks Ahead
Alnylam Pharmaceuticals’ fair value estimate has increased from $467.94 to $480.17. This change reflects analysts' optimism about robust Amvuttra sales, raised revenue guidance, and an improved profit margin outlook.Cardiomyopathy Launches And Pipeline Expansion Will Sustain Momentum Into 2025
Analysts have increased their price target for Alnylam Pharmaceuticals by approximately $16, citing stronger than expected product launches and continued commercial momentum. Analyst Commentary Following a series of upward price target revisions, Wall Street analysts remain broadly upbeat about Alnylam Pharmaceuticals’ near-term commercial performance and long-term prospects.RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals' analyst price targets have recently moved higher, with analysts citing stronger commercial performance of Amvuttra and encouraging data from pipeline assets as drivers behind the upward revisions. The cited targets have climbed by as much as $55 to $583 per share.RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam Pharmaceuticals’ price target was raised to $447.15 as analysts cited accelerating Amvuttra sales, positive clinical progress, robust financial execution, and increased revenue forecasts, reflecting growing confidence in the company’s commercial momentum and pipeline. Analyst Commentary Strong commercial momentum for Amvuttra, particularly in ATTR-CM, with sales trends and script data consistently exceeding expectations.RNAi Therapies Will Ensure Worldwide Market Expansion
Alnylam’s modestly lower consensus price target to $421.20 reflects both strong near-term Amvuttra uptake in ATTR-CM and positive revenue outlook, tempered by mixed KARDIA-3 data for zilebesiran and resulting slight valuation adjustment. Analyst Commentary Bullish analysts cited strong commercial performance and encouraging uptake for Amvuttra, particularly following its approval and launch in ATTR-CM (transthyretin amyloid cardiomyopathy), as a key driver for raising price targets.Need To Know: Analysts Are Much More Bullish On Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Aug 01
Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster
Mar 21Alnylam: Waiting For Regulatory Updates In March
Feb 13Alnylam Pharmaceuticals Q3 Earnings Preview: Key RNAi Catalysts To Watch
Oct 27Alnylam: HELIOS-B Success Priced In Already
Aug 30Rendimenti per gli azionisti
| ALNY | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -3.1% | -2.4% | 0.8% |
| 1Y | 14.2% | 27.4% | 27.8% |
Ritorno vs Industria: ALNY ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 27.4 % nell'ultimo anno.
Rendimento vs Mercato: ALNY ha avuto una performance inferiore al mercato US che ha registrato un rendimento 27.8 % nell'ultimo anno.
Volatilità dei prezzi
| ALNY volatility | |
|---|---|
| ALNY Average Weekly Movement | 5.4% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: ALNY non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di ALNY è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2002 | 2,500 | Yvonne Greenstreet | www.alnylam.com |
Alnylam Pharmaceuticals, Inc. scopre, sviluppa, produce e commercializza negli Stati Uniti, in Europa e a livello internazionale farmaci terapeutici basati sull'interferenza dell'acido ribonucleico. L'azienda offre ONPATTRO per l'amiloidosi ereditaria mediata dalla transtiretina (hATTR); AMVUTTRA per l'amiloidosi ATTR e hATTR; Leqvio per l'ipercolesterolemia; Qfitlia per l'emofilia A o B; GIVLAARI per la porfiria epatica acuta; e OXLUMO per l'iperossaluria primaria di tipo 1. L'azienda sviluppa anche una serie di prodotti in fase di sperimentazione 3, come Nucresiran per l'amiloidosi ATTR, Zilebesiran per l'ipertensione, Cemdisiran per la miastenia grave, l'emoglobinuria parossistica notturna e l'atrofia geografica ed Elebsiran per le infezioni da virus dell'epatite D. Inoltre, l'azienda sta sviluppando diversi prodotti in fase di sperimentazione 2, tra cui Rapirosiran per la steatoepatite associata a disfunzione metabolica; ALN-ANG3 per la malattia renale diabetica; ALN-4324 per il diabete mellito di tipo 2; Mivelsiran per l'angiopatia amiloide cerebrale, nonché in fase di sperimentazione 1 per la malattia di Alzheimer; e ALN-6400 per i disturbi emorragici.
Alnylam Pharmaceuticals, Inc. Riepilogo dei fondamenti
| ALNY statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$39.51b |
| Utili (TTM) | US$537.99m |
| Ricavi(TTM) | US$4.29b |
ALNY è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ALNY Conto economico (TTM) | |
|---|---|
| Ricavi | US$4.29b |
| Costo del fatturato | US$819.21m |
| Profitto lordo | US$3.47b |
| Altre spese | US$2.93b |
| Utili | US$537.99m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 4.03 |
| Margine lordo | 80.89% |
| Margine di profitto netto | 12.55% |
| Rapporto debito/patrimonio netto | 251.7% |
Come si è comportato ALNY nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/03 21:54 |
| Prezzo dell'azione a fine giornata | 2026/05/01 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Alnylam Pharmaceuticals, Inc. è coperta da 57 analisti. 25 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Huidong Wang | Barclays |
| Eliana Merle | Barclays |
| Emily Bodnar | Berenberg |